Mid-term effects of laparoscopic sleeve gastrectomy on metabolic syndrome
MetadataShow full item record
CitationBatman, B., & Altun, H. (2020). Mid-Term Effects of Laparoscopic Sleeve Gastrectomy on Metabolic Syndrome. Bariatric Surgical Practice and Patient Care, 15(1), 22-26.
Background: Obesity is associated with lower life expectancy and many comorbid diseases, including arterial hypertension, hyperlipidemia, and type 2 diabetes mellitus (T2DM), which is defined as metabolic syndrome (MetS). The aim of this study was to investigate the effects of laparoscopic sleeve gastrectomy (LSG) on parameters of MetS in obese patients 2 years after surgery. Methods: Between March 2013 and June 2019 1333 patients, who underwent LSG, were enrolled in this study; patients fulfilling the following conditions were considered eligible for LSG: body mass index (BMI) >= 40kg/m(2) or BMI >35kg/m(2) with comorbidities or BMI between 30 and 35kg/m(2) with T2DM or MetS. The patients were followed up by outpatient visits that were scheduled at 1st, 3rd, 6th, and 12th months postoperatively and annually thereafter. Results: One thousand three hundred and thirty-three patients underwent LSG. The mean age was 40.9310.86; 954 (71.5%) patients were female. After 2 years of surgery there was a significant improvement in glucose, glycosylated hemoglobin (HbA1c), insulin, the homeostasis model assessment insulin resistance, triglycerides, and high-density lipoprotein cholesterol (p<0.0001) with no significant reduction in serum total cholesterol (p=0.392) and low-density lipoprotein cholesterol (p=0.692) levels. Conclusions: LSG is an effective treatment for MetS and obesity related comorbidities.